The landmark Randomized Aldactone Evaluation Study (RALES), published in 1999, showed that spironolactone, a potassium-sparing diuretic, improves outcomes in patients with severe heart failure.

investigated whether adding the aldosterone receptor antagonist spironolactone to renin–angiotensin system inhibition improved proteinuria in patients with diabetic nephropathy. Patients with ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...